跳至主要内容
临床试验/NCT03369132
NCT03369132Unknown不适用

Efficacy of Natural Seawater Based Throat Spray in Acute Sore Throat Relief: a Prospective, Randomized, Double-blind, Placebo-controlled, Multicentre Clinical Study

Laboratoire de la Mer32 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2017年11月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
360
试验地点
32
主要终点
Sore Throat Relief

研究概览

简要总结

Prospective, randomized, double-blind, placebo-controlled, multicentre clinical trial to assess the efficacy and tolerability of natural seawater based throat spray among adult patients with acute sore throat.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (male or female) aged ≥ 18 years old.
  • Patients with complaint of sore throat ≤ 72h.
  • Sore throat exclusively due to upper respiratory tract infection (tonsillitis, pharyngitis, rhinopharyngitis).
  • Clinical confirmation by the physician for the presence of typical signs (spontaneous pain, local inflammation) of acute pharyngitis or tonsillitis.
  • Pain intensity scored by patient on the 5-point descriptive pain intensity scale as slight, mild or moderate.
  • Willingness to provide written informed consent prior to perform of any study related procedure.
  • Subjects agreeing to follow the study requirements during the whole study period (including forbidden medication and food supplements).
  • Subjects agreeing not to modify their lifestyle habits during the whole study period (diet, physical activity).
  • Subject affiliated to social security.
  • Subject able to understand verbal and written local language and in capacity to fill-in patient diary by himself/herself.

排除标准

  • Previous history of allergy or known intolerance to one of the following formulation ingredients: seawater, vegetable glycerin, mint, lemon, acacia honey, propolis, essential oils.
  • Active Smokers.
  • Fever > 38°C at randomization.
  • Past or current throat phlegmon.
  • Past or current seasonal allergy.
  • Past or current asthma.
  • Past or current chronic rhinosinusitis.
  • Past or current chronic obstructive pulmonary disease (COPD).
  • Past or current ENT (Ear, Nose and Throat) cancer.
  • Acute rhinosinusitis.
  • Controlled or uncontrolled diabetes.
  • Gastroesophageal reflux disease (GERD).
  • Known immunodeficiency.
  • Any painful condition that may distract attention from sore throat pain (ex: mouth ulcers etc.) or that requires analgesic usage.
  • Any disease that may interfere with the study aim from investigator's opinion.
  • Evidence of mouth breathing or severe coughing.
  • Patient with severe pain intensity on 5-point descriptive pain intensity scale.
  • Subjects taking:
  • chronic treatment for throat or other ENT pathology,
  • current antibiotherapy or stopped less than 2 weeks before inclusion,
  • chronic treatment (>3 months) with local or systemic corticotherapy, or immunotherapy,
  • local or systemic antihistaminic.
  • Subjects refusing to stop at entry into the study:
  • throat spray, lozenge, pastille,
  • local throat or systemic analgesic,
  • medicated confectionary,
  • nasal wash and spray,
  • nasal corticosteroid or antihistaminic nasal spray,
  • medication to gargle,
  • honey, propolis, or any sore throat home remedies.
  • Known liver disease or hypersensitivity to paracetamol.
  • Pregnant, breastfeeding or seeking pregnancy women.
  • Positive result from rapid strep throat test.
  • Subjects already included once in this study.
  • Subjects participating in another clinical trial or in the exclusion period to another study.
  • Subjects having a member of his/her home who is currently participating to this study.

研究组 & 干预措施

Angiflash

Experimental

干预措施: Angiflash (Device)

Placebo

Placebo Comparator

干预措施: Placebo (Device)

结局指标

主要结局

Sore Throat Relief

时间窗: Over the first three days

Evaluation of sore throat relief using the 7-point sore throat relief scale (STRS)

次要结局

  • Product Satisfaction(Day 8)
  • Sore Throat Pain Intensity(Day 1, 2, 3, 4, 5, 5, 7 to 8.)
  • Difficulty Swallowing(Day 1, 2, 3, 4, 5, 5, 7 to 8.)
  • Overall efficacy assessed by the physician(Day 8)
  • Incidence of adverse events occuring during the study(Day 1, 2, 3, 4, 5, 5, 7 to 8.)
  • Sore Throat Individual Symptoms Relief(Day 1, 2, 3, 4, 5, 5, 7 to 8.)
  • Swollen Throat(Day 1, 2, 3, 4, 5, 5, 7 to 8.)
  • Compliance: assessment of the number of use per day and the number of spray per use(Day 1, 2, 3, 4, 5, 5, 7 to 8.)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (32)

Loading locations...

相似试验